Dai Shangnan, Peng Yunpeng, Wang Guangfu, Chen Chongfa, Chen Qiuyang, Yin Lingdi, Yan Han, Zhang Kai, Tu Min, Lu Zipeng, Wei Jishu, Li Qiang, Wu Junli, Jiang Kuirong, Zhu Yi, Miao Yi
Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu Province, PR China.
Pancreas Institute, Nanjing Medical University, Nanjing, 210029, Jiangsu Province, PR China.
Cell Death Differ. 2025 Feb;32(2):271-290. doi: 10.1038/s41418-024-01358-7. Epub 2024 Aug 14.
With advancements in genomics and immunology, immunotherapy has emerged as a revolutionary strategy for tumor treatment. However, pancreatic ductal adenocarcinoma (PDAC), an immunologically "cold" tumor, exhibits limited responsiveness to immunotherapy. This study aimed to address the urgent need to uncover PDAC's immune microenvironment heterogeneity and identify the molecular mechanisms driving immune evasion. Using single-cell RNA sequencing datasets and spatial proteomics, we discovered LIM domain only 7 (LMO7) in PDAC cells as a previously unrecognized driver of immune evasion through Treg cell enrichment. LMO7 was positively correlated with infiltrating regulatory T cells (Tregs) and dysfunctional CD8 T cells. A series of in vitro and in vivo experiments demonstrated LMO7's significant role in promoting Treg cell differentiation and chemotaxis while inhibiting CD8 T cells and natural killer cell cytotoxicity. Mechanistically, LMO7, through its LIM domain, directly bound and promoted the ubiquitination and degradation of Foxp1. Foxp1 negatively regulated transforming growth factor-beta (TGF-β) and C-C motif chemokine ligand 5 (CCL5) expression by binding to sites 2 and I/III, respectively. Elevated TGF-β and CCL5 levels contribute to Treg cell enrichment, inducing immune evasion in PDAC. Combined treatment with TGF-β/CCL5 antibodies, along with LMO7 inhibition, effectively reversed immune evasion in PDAC, activated the immune response, and prolonged mouse survival. Therefore, this study identified LMO7 as a novel facilitator in driving immune evasion by promoting Treg cell enrichment and inhibiting cytotoxic effector functions. Targeting the LMO7-Foxp1-TGF-β/CCL5 axis holds promise as a therapeutic strategy for PDAC. Graphical abstract revealing LMO7 as a novel facilitator in driving immune evasion by promoting Tregs differentiation and chemotaxis, inducing CD8 T/natural killer cells inhibition.
随着基因组学和免疫学的进步,免疫疗法已成为肿瘤治疗的一种革命性策略。然而,胰腺导管腺癌(PDAC)作为一种免疫“冷”肿瘤,对免疫疗法的反应有限。本研究旨在满足迫切需求,即揭示PDAC免疫微环境的异质性并确定驱动免疫逃逸的分子机制。利用单细胞RNA测序数据集和空间蛋白质组学,我们在PDAC细胞中发现了仅含LIM结构域7(LMO7),它是一种先前未被认识的通过富集调节性T细胞(Treg)来驱动免疫逃逸的因子。LMO7与浸润性调节性T细胞(Tregs)和功能失调的CD8 T细胞呈正相关。一系列体外和体内实验表明,LMO7在促进Treg细胞分化和趋化作用方面具有重要作用,同时抑制CD8 T细胞和自然杀伤细胞的细胞毒性。从机制上讲,LMO7通过其LIM结构域直接结合并促进Foxp1的泛素化和降解。Foxp1分别通过与位点2和I/III结合,负向调节转化生长因子-β(TGF-β)和C-C基序趋化因子配体5(CCL5)的表达。TGF-β和CCL5水平升高有助于Treg细胞富集,从而在PDAC中诱导免疫逃逸。联合使用TGF-β/CCL5抗体以及抑制LMO7,可有效逆转PDAC中的免疫逃逸,激活免疫反应并延长小鼠生存期。因此,本研究确定LMO7是通过促进Treg细胞富集和抑制细胞毒性效应功能来驱动免疫逃逸的新型促进因子。靶向LMO7-Foxp1-TGF-β/CCL5轴有望成为PDAC的一种治疗策略。揭示LMO7作为通过促进Tregs分化和趋化作用、诱导CD8 T/自然杀伤细胞抑制来驱动免疫逃逸的新型促进因子的示意图摘要